A5089375994- Parkinson's Disease Mechanisms and Treatments
- Synthesis and biological activity
- Neuroscience and Neuropharmacology Research
- Synthesis and Characterization of Heterocyclic Compounds
- Nuclear Receptors and Signaling
- Synthesis and Reactions of Organic Compounds
- Structural and Chemical Analysis of Organic and Inorganic Compounds
- Neurotransmitter Receptor Influence on Behavior
- Neurological disorders and treatments
- Chemical Synthesis and Analysis
- Nerve injury and regeneration
- Genetic Neurodegenerative Diseases
- Amino Acid Enzymes and Metabolism
- Sphingolipid Metabolism and Signaling
- Synthesis and Biological Evaluation
- Synthesis of heterocyclic compounds
- Synthesis and Catalytic Reactions
- Photopolymerization techniques and applications
- Sulfur-Based Synthesis Techniques
- Drug Transport and Resistance Mechanisms
- Biochemical and Molecular Research
- Crystal structures of chemical compounds
- Ocular Surface and Contact Lens
- Fungal Plant Pathogen Control
- Neurological Disorders and Treatments
Koltzov Institute of Developmental Biology
2020-2024
Russian Academy of Sciences
2022
Institute of Developmental Physiology
2022
Kirov State Medical Academy
1972-1975
Parkinson's disease (PD) is diagnosed many years after its onset, under a significant degradation of the nigrostriatal dopaminergic system, responsible for regulation motor function. This explains low effectiveness treatment patients. Therefore, one highest priorities in neurology development early (preclinical) diagnosis PD. The aim this study was to search changes blood patients at risk developing PD, which are considered potential diagnostic biomarkers. Out 1835 patients, 26 were included...
Parkinson’s disease (PD) is diagnosed by the onset of motor symptoms and treated long after its onset. Therefore, development early diagnosis PD a priority for neurology. Advanced methodologies this include (1) searching patients at risk developing prodromal based on premotor symptoms; (2) changes in body fluids these as diagnostic biomarkers; (3) verifying diagnostic-value biomarkers using positron emission tomography (PET); (4) anticipating symptoms. According to our data, majority (n =...
Development of differential and early (preclinical) diagnostics Parkinson’s disease (PD) is among the priorities in neuroscience. We searched for changes level catecholamines α-2-macroglobulin activity tear fluid (TF) PD patients at an clinical stage. It was shown that TF characterized by increased noradrenaline mainly on ipsilateral side pronounced motor symptoms (72%, p = 0.049), a decreased adrenaline both sides (ipsilateral—53%, 0.004; contralateral—42%, 0.02), 0.03; contralateral—56%,...
The mammalian striatum is known to contain non-dopaminergic neurons that express dopamine (DA)-synthesizing enzymes and produce DA, responsible for the regulation of motor function. This study assessed expression DA-synthesizing in striatal their role DA synthesis transgenic mice expressing green fluorescent protein (GFP) gene under tyrosine hydroxylase (TH) promoter a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model Parkinson’s disease (PD). We showed that, Parkinsonian animals,...
Since the discovery of striatal neurons expressing dopamine-synthesizing enzymes, researchers have attempted to identify their phenotype and functional significance. In this study, it was shown that in transgenic mice green fluorescent protein (GFP) under tyrosine hydroxylase (TH) gene promoter, (i) there are only TH, aromatic L-amino acid decarboxylase (AADC), or both enzymes dopamine synthesis; (ii) not dopaminergic since they lack a transporter; (iii) monoenzymatic individual...
Parkinson's disease (PD) is a neurodegenerative incurable due to late diagnosis and treatment. Therefore, one of the priorities neurology study mechanisms PD pathogenesis at preclinical early clinical stages. Given important role sphingolipids in diseases, we aimed analyze gene expression key sphingolipid metabolism enzymes (ASAH1, ASAH2, CERS1, CERS3, CERS5, GBA1, SMPD1, SMPD2, UGCG) content 32 (subspecies ceramides, sphingomyelins, monohexosylceramides sphinganine, sphingosine,...
Since the 1980s, concept of dopamine-rich brain centers as clusters only dopaminergic neurons has been fundamentally revised. It shown that, in addition to neurons, most these contain expressing one enzymes dopamine synthesis: tyrosine hydroxylase (TH) or aromatic L-amino acid decarboxylase (AADC). We have obtained convincing evidence that rats, hypothalamic periventricular nucleus (PeVN) is largest centers, containing and monoenzymatic neurons. Indeed, using double immunostaining for TH...
Dopaminergic neurons (DNs) of the nigrostriatal system control motor function, and their degeneration leads to development Parkinson’s disease (PD). A stumbling block in study DNs whole substantia nigra (SN) is lack tools analyze expression most genes involved neurotransmission, neurodegeneration, neuroplasticity, since they are also expressed other cells SN. Therefore, this aimed develop a fluorescence-activated cell sorting method for isolating living from SN wild-type mice using two...
Background: The aim of our study was to determine the role sphingolipids, which control proliferation and apoptosis, in placenta pregnant women with pregnancy-associated breast cancer (PABC) after chemotherapy compared healthy patients. Methods: We analyzed (by PCR method) gene expression key sphingolipid metabolism enzymes (sphingomyelinases (SMPD1 SMPD3), acid ceramidase (ASAH1), ceramide synthases (CERS 1–6), sphingosine kinase1 (SPHK1), sphingosine-1-phosphate lyase 1 (SGPL1), receptors...
The low effectiveness of symptomatic pharmacotherapy for Parkinson’s disease (PD), which compensates dopamine (DA) deficiency under degeneration nigrostriatal dopaminergic (DAergic) neurons, could apparently be improved with neuroprotective therapy, slows down neurodegeneration and PD progression. For this, it is necessary to have a DAergic cell line the development model screen neuroprotectors. We used immortalized human embryonic mesencephalon LUHMES cells (LCs) differentiated into...
The paper summarizes the literature and author's data on development of early (preclinical) diagnosis Parkinson's disease (PD). Implementation this will promote use preventive therapy change investments in treatment patients. declares that at present only approach to PD is positron-emission tomography nigrostriatal dopaminergic system, but it cannot be used for examination due its high cost. authors consider a less specific, more promising search markers body fluids, mainly blood, patients...
This is the first study aiming to develop a method for long-term visualization of living nigrostriatal dopaminergic neurons using 1-(2-(bis(4-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl)piperazine-BODIPY (GBR-BP), original fluorescent substance, which derivative GBR-12909, dopamine uptake inhibitor. based on authors' hypothesis about possibility specifically internalizing into substances with high affinity transporter (DAT). Using culture mouse embryonic mesencephalic and LUHMES cells...
OBJECTIVE To determine changes in the chemical composition of blood plasma subjects at risk Parkinson's disease (PD) prodromal stage compared with age control. MATERIAL AND METHODS Subjects were selected for presence characteristic premotor symptoms, including impairments sleep, olfaction and constipation.The group included 12 people, control - 8 people. RESULTS Among seven catecholamines their metabolites detected blood, only concentration L-dioxiphenylalanine (L-DOPA) changed (decreased) A...
Studying the molecular mechanisms of pathogenesis Parkinson’s disease (PD) is critical to improve PD treatment. We used OpenArray technology assess gene expression in substantia nigra (SN) cells mice a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model and controls. Among 11 housekeeping genes tested, Rps27a was taken as reference due its most stable normal experimental conditions. From 101 encoding functionally significant proteins nigrostriatal dopaminergic neurons, 57 highly...
Болезнь Паркинсона (БП) является хроническим и прогрессирующим нейродегенеративным заболеванием, развивающимся в результате повреждения гибели дофаминергических нейронов чёрной субстанции. Клинический диагноз БП определяют спустя много лет от начала развития заболевания, когда значительная часть пула нигростриатных дофаминергичеких погибает. Возможно, с этим связана относительная низкая эффективность применяемой заместительной терапии виде леводопасодержащих препаратов. В связи главным...